About this trial
Cortical transit time on diuretic renogram as an early marker of significant obstruction in antenatally detected uretero-pelvic junction syndrome
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged of 4 to 8 weeks of life
Presenting an ureteropelvic junction obstruction (UPJO) detected before birth by ultrasound
Presenting an UPJO, defined by an Antero-Posterior Renal Pelvic Diameter greater or equal to 15 mm, confirmed by ultrasound post-natally between the 1st and 15th day of life
Presenting a unilateral UPJO
Disqualifiers
A bilateral UPJO
An ureteral dilatation
An associated contralateral uropathy
A solitary kidney
Trial design
Single group
Treatments tested in this trial
ultrasonography
Devicebilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
diuretic renography
Devicediuretic renography to measure the cortical transit time.
Treatment groups
Trial outcomes
Primary outcomes
risk, during the first year of life, of an increase of 4mm or more in the measure of APRPD by ultrasonography as compared to the baseline measure, according to the presence or not of an abnormal cortical transit ti
During the first year of life, the antero-posterior renal pelvic diameter will be measured by ultrasonography at baseline, then at 3 months, 6 months and 12 months after baseline. Diuretic renography will be performed only at baseline and the cortical transit time will be classified as normal or abnormal. An increase of 4mm or more of APRPD is the threshold chosen in the study to determine the aggravation of hydronephrosis. The occurence of the increase of 4mm or more in the measure of APRPD will be compared with the normality/abnormality of the cortical transit time in order to determine its value as a prognostic marker.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.